导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.88% | 1517/4763 |
| 近一周 | -1.26% | 1902/5452 |
| 近一月 | -8.06% | 4745/5409 |
| 近一季 | -17.96% | 4648/5219 |
| 近半年 | -0.57% | 1509/4908 |
| 近一年 | 7.61% | 1448/4388 |
| 近两年 | 108.55% | 563/2951 |
| 近三年 | 64.08% | 423/2250 |
| 成立以来 | 159.48% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.57% 1853/4961 |
34.31% 958/5312 |
- - |
- - |
| 2025 | 47.74% 555/4813 |
-1.59% 2701/3635 |
3.15% 1137/4076 |
46.97% 499/4524 |
-0.97% 2751/4813 |
| 2024 | 12.70% 1220/3463 |
-3.73% 1554/2808 |
-6.13% 1860/3014 |
27.38% 228/3129 |
-2.10% 1956/3463 |
| 2023 | -17.87% 1766/2656 |
1.99% 1471/2280 |
-6.78% 1707/2385 |
-8.91% 1748/2515 |
-5.17% 1279/2655 |
| 2022 | -26.97% 1446/2207 |
-18.54% 1352/1919 |
5.84% 817/2016 |
-17.24% 1569/2113 |
2.36% 960/2208 |
| 2021 | 13.21% 363/1822 |
-6.09% 976/1255 |
25.04% 101/1330 |
-5.97% 885/1466 |
2.54% 567/1822 |
| 2020 | 63.22% 110/1250 |
4.11% 87/1028 |
28.62% 98/1067 |
6.42% 840/1164 |
14.53% 267/1184 |
| 2019 | 39.79% 270/1092 |
32.11% 179/739 |
-9.65% 678/788 |
7.09% 102/850 |
9.36% 231/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时创业板ETF联接C VS. 长安沪深300非周期A(740101) |